Improved antitumoral treatments using PM02734 and an EGFR tyrosine kinase inhibitor (erlotinib)

摘要

Disclosed is the use of PM02734, or a pharmaceutical acceptable salt thereof, in combination with an EGFR tyrosine kinase inhibitor, or a pharmaceutical acceptable salt thereof, for the manufacture of a medicament for the treatment of a cancer, wherein the medicament comprises synergistic properties.